CPSE:CHR

Stock Analysis Report

Chr. Hansen Holding

Executive Summary

Chr. Hansen Holding A/S, a bioscience company, develops and sells natural ingredient solutions for food, nutritional, pharmaceutical, and agricultural industries in Europe, the Middle East, Africa, North America, Latin America, and the Asia-Pacific.

Snowflake

Fundamentals

Solid track record with moderate growth potential.


Similar Companies

Share Price & News

How has Chr. Hansen Holding's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-6.3%

CHR

0.9%

DK Chemicals

0.2%

DK Market


1 Year Return

-20.2%

CHR

3.0%

DK Chemicals

12.2%

DK Market

Return vs Industry: CHR underperformed the Danish Chemicals industry which returned 3% over the past year.

Return vs Market: CHR underperformed the Danish Market which returned 12.2% over the past year.


Shareholder returns

CHRIndustryMarket
7 Day-6.3%0.9%0.2%
30 Day-8.8%1.4%-1.5%
90 Day-12.7%0.9%1.3%
1 Year-18.6%-20.2%7.0%3.0%15.5%12.2%
3 Year43.9%34.6%20.5%9.8%34.2%23.0%
5 Year145.9%120.1%53.7%31.0%69.0%44.9%

Price Volatility Vs. Market

How volatile is Chr. Hansen Holding's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Chr. Hansen Holding undervalued compared to its fair value and its price relative to the market?

36.66x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: CHR (DKK520.2) is trading above our estimate of fair value (DKK242.19)

Significantly Below Fair Value: CHR is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: CHR is poor value based on its PE Ratio (36.7x) compared to the Chemicals industry average (17.1x).

PE vs Market: CHR is poor value based on its PE Ratio (36.7x) compared to the Danish market (14.8x).


Price to Earnings Growth Ratio

PEG Ratio: CHR is poor value based on its PEG Ratio (4.1x)


Price to Book Ratio

PB vs Industry: CHR is overvalued based on its PB Ratio (11.5x) compared to the XE Chemicals industry average (1.6x).


Next Steps

Future Growth

How is Chr. Hansen Holding forecast to perform in the next 1 to 3 years based on estimates from 12 analysts?

9.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CHR's forecast earnings growth (9% per year) is above the savings rate (0.2%).

Earnings vs Market: CHR's earnings (9% per year) are forecast to grow slower than the Danish market (12.1% per year).

High Growth Earnings: CHR's earnings are forecast to grow, but not significantly.

Revenue vs Market: CHR's revenue (7.1% per year) is forecast to grow faster than the Danish market (6.8% per year).

High Growth Revenue: CHR's revenue (7.1% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: CHR's Return on Equity is forecast to be high in 3 years time (25.2%)


Next Steps

Past Performance

How has Chr. Hansen Holding performed over the past 5 years?

12.3%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: CHR's earnings have grown by 12.3% per year over the past 5 years.

Accelerating Growth: CHR's earnings growth over the past year (9.6%) is below its 5-year average (12.3% per year).

Earnings vs Industry: CHR earnings growth over the past year (9.6%) exceeded the Chemicals industry 1.5%.


Return on Equity

High ROE: CHR's Return on Equity (31.4%) is considered high.


Return on Assets

ROA vs Industry: CHR has a higher Return on Assets than the Chemicals industry average last year.


Return on Capital Employed

ROCE Improving: CHR has improved its Return on Capital Employed over the past 3 years.


Next Steps

Financial Health

How is Chr. Hansen Holding's financial position?


Financial Position Analysis

Short Term Liabilities: CHR's short term assets (€474.0M) exceeds its short term liabilities (€360.9M)

Long Term Liabilities: CHR's short term assets (474.0M) do not cover its long term liabilities (899.7M)


Debt to Equity History and Analysis

Debt Level: CHR's debt to equity ratio (96%) is considered high

Reducing Debt: CHR's debt to equity ratio has increased from 70.3% to 96% over the past 5 years.

Debt Coverage: CHR's debt is well covered by operating cash flow (39%).

Interest Coverage: CHR's interest payments on its debt are well covered by EBIT (30.9x coverage).


Balance Sheet

Inventory Level: CHR has a high level of physical assets or inventory.

Debt Coverage by Assets: CHR's debt is not covered by short term assets (assets are 0.6x debt).


Next Steps

Dividend

What is Chr. Hansen Holding's current dividend yield, its reliability and sustainability?

2.57%

Current Dividend Yield


Upcoming Dividend Payment

Purchase Chr. Hansen Holding before the 'Buy Limit' to receive their next dividend payment.


Dividend Yield vs Market

company2.6%marketbottom25%1.7%markettop25%5.2%industryaverage3.1%forecastin3Years2.0%

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: CHR's dividend (2.57%) is higher than the bottom 25% of dividend payers in the Danish market (1.73%).

High Dividend: CHR's dividend (2.57%) is low compared to the top 25% of dividend payers in the Danish market (5.17%).

Stable Dividend: CHR has been paying a dividend for less than 10 years and during this time payments have been volatile.

Growing Dividend: CHR's dividend payments have increased, but the company has only paid a dividend for 9 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonable payout ratio (50%), CHR's dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: CHR's dividends in 3 years are forecast to be covered by earnings (63.5% payout ratio).


Next Steps

Management

What is the CEO of Chr. Hansen Holding's salary, the management and board of directors tenure and is there insider trading?

3.1yrs

Average management tenure


CEO

Mauricio Graber (56yo)

1.3yrs

Tenure

€3,101,000

Compensation

Mr. Mauricio Graber has been Chief Executive Officer, President and Member of Executive Board of Chr. Hansen Holding A/S since joining it on June 1, 2018. Mr. Graber served as the President of Flavour Divi ...


CEO Compensation Analysis

Compensation vs. Market: Mauricio has recently become CEO, making it difficult to compare their total compensation against companies of similar size in the Danish market.

Compensation vs Earnings: Mauricio's compensation has been consistent with company performance over the past year.


Management Age and Tenure

3.1yrs

Average Tenure

50.5yo

Average Age

Experienced Management: CHR's management team is considered experienced (3.1 years average tenure).


Board Age and Tenure

1.9yrs

Average Tenure

59yo

Average Age

Experienced Board: CHR's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Alice Larsen (51yo)

    Corporate Vice President of Global Human Resources

    • Tenure: 3.3yrs
  • Søren Lonning (42yo)

    CFO, Executive VP & Member of Executive Board

    • Tenure: 4.2yrs
    • Compensation: €966.00k
  • Mauricio Graber (56yo)

    CEO, President & Member of Executive Board

    • Tenure: 1.3yrs
    • Compensation: €3.10m
  • Winnie Bügel (54yo)

    Corporate Vice President of Compliance

    • Tenure: 3.3yrs
  • Jacob Paulsen (43yo)

    Executive Vice President of Food Cultures & Enzymes

    • Tenure: 3.1yrs
  • Thomas Schäfer (56yo)

    Executive VP

    • Tenure: 1.9yrs
    • Compensation: €636.00k
  • Christian Barker (49yo)

    Executive Vice President of Health & Nutrition

    • Tenure: 0yrs
  • Camilla Lercke

    Head of Media Relations

    • Tenure: 0yrs
  • Torsten Steenholt (50yo)

    Executive Vice President of Global Operations

    • Tenure: 2.8yrs
  • Martin Riise

    Head of Investor Relations

    • Tenure: 0yrs

Board Members

  • Jesper Brandgaard (56yo)

    Independent Vice Chairman

    • Tenure: 0yrs
    • Compensation: €127.00k
  • Dominique J. Reiniche (64yo)

    Independent Chairman of the Board

    • Tenure: 0.9yrs
    • Compensation: €217.00k
  • Luis Cantarell Rocamora (67yo)

    Independent Director

    • Tenure: 2.9yrs
    • Compensation: €88.00k
  • Mark Wilson (67yo)

    Independent Director

    • Tenure: 9yrs
    • Compensation: €129.00k
  • Heidi Kleinbach-Sauter (62yo)

    Director

    • Tenure: 1.9yrs
    • Compensation: €87.00k
  • Kristian Villumsen (49yo)

    Independent Director

    • Tenure: 4.9yrs
    • Compensation: €91.00k
  • Per Poulsen (53yo)

    Employee Representative Director

    • Tenure: 5.9yrs
    • Compensation: €54.00k
  • Lisbeth Grubov (64yo)

    Employee Representative Director

    • Tenure: 1.9yrs
    • Compensation: €57.00k
  • Charlotte Hemmingsen (55yo)

    Employee Representative Director

    • Tenure: 1.9yrs
    • Compensation: €54.00k
  • Kim Soerensen (56yo)

    Employee Representative Director

    • Tenure: 1.9yrs
    • Compensation: €57.00k

Company Information

Chr. Hansen Holding A/S's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Chr. Hansen Holding A/S
  • Ticker: CHR
  • Exchange: CPSE
  • Founded: 1874
  • Industry: Specialty Chemicals
  • Sector: Materials
  • Market Cap: ø68.503b
  • Shares outstanding: 131.69m
  • Website: https://www.chr-hansen.com

Number of Employees


Location

  • Chr. Hansen Holding A/S
  • Bøge Allé 10-12
  • Hørsholm
  • Capital Region of Denmark
  • 2970
  • Denmark

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CHRCPSE (OMX Nordic Exchange Copenhagen)YesShare CapitalDKDKKJun 2010
51CDB (Deutsche Boerse AG)YesShare CapitalDEEURJun 2010
0MR6LSE (London Stock Exchange)YesShare CapitalGBDKKJun 2010
CRTS.FOTCPK (Pink Sheets LLC)YesShare CapitalUSUSDJun 2010
CHRCBATS-CHIXE (BATS 'Chi-X Europe')YesShare CapitalGBDKKJun 2010
CHYH.YOTCPK (Pink Sheets LLC)SPONSORED ADSUSUSDMay 2012

Biography

Chr. Hansen Holding A/S, a bioscience company, develops and sells natural ingredient solutions for food, nutritional, pharmaceutical, and agricultural industries in Europe, the Middle East, Africa, North A ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/22 21:11
End of Day Share Price2019/10/22 00:00
Earnings2019/08/31
Annual Earnings2019/08/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.